Does rapamycin help humans live longer? A large transplant study finds no clear survival benefit
An observational analysis of 11,474 kidney transplant recipients found similar adjusted median survival ages whether or not they were prescribed an mTOR inhibitor.
AgeBeacon editorial summary · Source publication:
Why it matters
Rapamycin extends lifespan in several animal models, but whether this translates to humans is unproven. Researchers used US national transplant records to compare 4,885 recipients prescribed mTOR inhibitors with 6,589 who were not. Median follow-up was roughly 11 years. After adjustment for demographic and clinical differences, median survival age was 64.6 years with mTOR inhibition and 64.3 years without it; the estimated difference was not statistically significant (95% confidence interval: -1.6 to +2.0 years). This study did not demonstrate that treatment lengthens life.
Beacon take
This is useful long-term human evidence, but it cannot settle whether intermittent, low-dose rapamycin benefits otherwise healthy adults. Transplant recipients have serious underlying illness, use other immunosuppressants and may receive quite different dosing. The study was observational, so residual confounding and changes in treatment remain possible. The outcome was survival, not an aging biomarker, and the null result deserves attention alongside promising animal experiments. Rapamycin can cause important adverse effects; it is not approved as an anti-aging therapy. A clinical trial in the intended population is needed to show longevity benefit.
Read the source
This is an AgeBeacon interpretation of research published elsewhere. Check the original paper or record for methods, results and limitations.